Crain's Chicago Business

Pathos raises $365 million in funding round, touts $1.6 billion valuation

Gift Article 10 Remaining As a subscriber, you have 10 articles to gift each month. Gifting allows recipients to access the article for free. Pathos AI, the biotech drug developer spun out of Tempus ...
FierceBiotech

Pathos AI secures $365M series D to fund trial of Novo Nordisk solid tumor drug

Pathos AI has secured $365 million in a series D raise as the artificial-intelligence-powered biotech looks to fund trials of solid tumor drugs sourced from Novo Nordisk and Prelude Therapeutics. The ...
Crain's Chicago Business

Tempus exec-founded Pathos AI launched a $400M funding round. It's already filling up.

Gift Article 10 Remaining As a subscriber, you have 10 articles to gift each month. Gifting allows recipients to access the article for free. Pathos AI has launched a $400 million funding round and ...
War on the Rocks

Pathos, Where Art Thou? Intelligence Analysis and Ethical Persuasion

While teaching a class on intelligence and analysis last year, I asked my graduate students why the media’s shocking picture of the drowned Syrian boy seemed to have such an incredible effect on ...
Seeking Alpha

Rain Oncology to be acquired by Pathos AI for $1.16 in cash per share

Rain Oncology (NASDAQ:RAIN) has agreed to be acquired by Pathos AI for $1.16, per share in cash and a potential cash payments of up to approximately $0.17 per share. Based in Newark, California the ...
Yahoo Finance

Pathos AI Closes $62M Oversubscribed Series C Round of Financing to Accelerate its Platform Approach to Drug Development

CHICAGO, Oct. 29, 2024 (GLOBE NEWSWIRE) -- Pathos AI, a clinical-stage biotechnology company focused on re-engineering drug development through artificial intelligence, today announced the closing of ...